Early-onset Prostate Cancer Is Frequent, Aggressive
the Cancer Therapy Advisor take:
This year, out of the 241,740 Americans diagnosed with prostate cancer, 10% of those diagnoses will be for early onset disease. Patients with prostate cancer are usually 70 to 80 years old, and their cancers are slow-growing. In the last 20 years, the number of younger men, defined as patients under 61 years, diagnosed with prostate cancer has multiplied by sixfold.
According to a study published in the journal Nature Reviews: Urology, prostate cancer in younger men has a higher chance of being aggressive. Kathleen A. Cooney, MD, and researchers at the University of Michigan Comprehensive Cancer Center. conducted a study in which they compared normal and cancerous prostate cancer tissue and DNA in younger men. They researched whether younger men with prostate cancer tend to have inherited genetic mutations, and they indeed found more genetic variants in patients who were diagnosed at a younger age than patients who were diagnosed at an older age.
Cooney said these findings suggest that for patients with early onset prostate cancer, a new subtype might exist that requires more specialty expertise. In addition, Cooney said that screenings may miss the rapidly growing tumors due to a short time frame before patients experience clinical symptoms.

Early-onset Prostate Cancer Is Frequent, Aggressive
The number of younger men diagnosed with prostate cancer has increased nearly 6-fold in the last 20 years, and the disease is more likely to be aggressive in these younger men, according to a new analysis from researchers at the University of Michigan Comprehensive Cancer Center. His PSA was only 9, but the disease had already spread to his ribs, spine and lymph nodes.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin on Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer